Therapeutic considerations in selected forms of acute and chronic liver disease.
D000208:Acute Disease; D000367:Age Factors; D000437:Alcoholism / Q000150:complications; D001379:Azathioprine / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D002908:Chronic Disease; D003348:Cortisone / Q000627:therapeutic use; D004035:Diet Therapy; D005078:Exchange Transfusion, Whole Blood; D006221:Halothane / Q000009:adverse effects; D006501:Hepatic Encephalopathy / Q000139:chemically induced / Q000145:classification / Q000209:etiology / Q000401:mortality / Q000628:therapy; D006505:Hepatitis / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D006506:Hepatitis A / Q000150:complications / Q000628:therapy; D006509:Hepatitis B / Q000150:complications; D006511:Hepatitis B Antigens / Q000032:analysis; D006760:Hospitalization; D006801:Humans; D008107:Liver Diseases / Q000628:therapy*; D008111:Liver Function Tests; D008286:Malabsorption Syndromes / Q000628:therapy; D015122:Mercaptopurine / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D011537:Pruritus / Q000628:therapy
D006511:Hepatitis B Antigens; D015122:Mercaptopurine; D001379:Azathioprine; D006221:Halothane; D003348:Cortisone; D011241:Prednisone